Tolvaptan delays the onset of end-stage renal disease in a Polycystic Kidney disease model by suppressing increases in Kidney volume and Renal Injury

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 2, 2014, Pages 258-267

  Aihara, Miki ^a   Fujiki, Hiroyuki ^a   Mizuguchi, Hiroshi ^a   Hattori, Katsuji ^a   Ohmoto, Koji ^a   Ishikawa, Makoto ^a   Nagano, Keisuke ^a   Yamamura, Yoshitaka ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TOLVAPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUARESIS; ARTICLE; CONTROLLED STUDY; DIURESIS; DOSE RESPONSE; DRUG POTENCY; END STAGE RENAL DISEASE; ENZYME ACTIVITY; KIDNEY INJURY; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; LONG TERM CARE; MALE; MORTALITY; MOUSE; NEPHRONOPHTHISIS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; SHORT COURSE THERAPY; SURVIVAL;

ACUTE-PHASE PROTEINS; ANIMALS; BENZAZEPINES; CYCLIC AMP; KIDNEY; KIDNEY FAILURE, CHRONIC; LIPOCALINS; MAGNETIC RESONANCE IMAGING; MALE; MICE; ONCOGENE PROTEINS; ORGAN SIZE; POLYCYSTIC KIDNEY DISEASES; RECEPTORS, VASOPRESSIN; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84898814885     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.213256     Document Type: Article

References (50)

1. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M, Ruel N, Bouby N, and Bankir L (2003a) Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-Angiotensin system. Nephrol Dial Transplant 18:497-506
2. Bardoux P, Bruneval P, Heudes D, Bouby N, and Bankir L (2003b) Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 18:1755-1763
3. Chang MY and Ong AC (2012) Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract 120:c25-c34, discussion c35
4. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, and Wetzel LH, et al. (2012) Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7:479-486
5. Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, Charasse C, Whebe B, Renaudineau E, and Jousset P, et al. (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24:1006-1013
6. Doctor RB, Serkova NJ, Hasebroock KM, Zafar I, and Edelstein CL (2010) Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice. Nephrol Dial Transplant 25:3496-3504
7. Furukawa M, Umehara K, and Kashiyama E (2011) Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan. Cardiovasc Drugs Ther 25 (Suppl 1):S83-S89
8. Gattone VH, 2nd, Wang X, Harris PC, and Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323-1326
9. Grantham JJ (2008) Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 359:1477-1485
10. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF, Jr., Wetzel LH, Baumgarten DA, Kenney PJ, and Harris PC, et al. CRISP Investigators (2006) Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130
11. Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, and Ravine D; European PKD1-PKD2 Study Group (1999) Comparison of phenotypes of polycystic kidney disease type 1 and 2. Lancet 353: 103-107
12. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, and Krasa HB, et al.; TEMPOFormula and 156-05-002 Study Investigators (2011) Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 6:2499-2507
13. Hirano T, Yamamura Y, Nakamura S, Onogawa T, and Mori T (2000) Effects of the V (2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292:288-294
14. Husson H, Manavalan P, Akmaev VR, Russo RJ, Cook B, Richards B, Barberio D, Liu D, Cao X, and Landes GM, et al. (2004) New insights into ADPKD molecular pathways using combination of SAGE and microarray technologies. Genomics 84: 497-510
15. Kondo K, Ogawa H, Yamashita H, Miyamoto H, Tanaka M, Nakaya K, Kitano K, Yamamura Y, Nakamura S, and Onogawa T, et al. (1999) 7-Chloro-5-hydroxy-1-[2- methyl-4-(2-methylbenzoyl-Amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg Med Chem 7:1743-1754
16. Koyner JL, Garg AX, Coca SG, Sint K, Thiessen-Philbrook H, Patel UD, Shlipak MG, and Parikh CR; TRIBE-AKI Consortium (2012) Biomarkers predict progression of acute kidney injury after cardiac surgery. J Am Soc Nephrol 23:905-914
17. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Yoshioka T, Ogawa Y, Imamaki H, and Kusakabe T, et al. (2009) Urinary neutrophil gelatinase-Associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 75:285-294
18. Lu W, Fan X, Basora N, Babakhanlou H, Law T, Rifai N, Harris PC, Perez-Atayde AR, Rennke HG, and Zhou J (1999) Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes. Nat Genet 21:160-161
19. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, and Larusso NF (2013) Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 58:409-421
20. Matsuzaki M, Hori M, Izumi T, and Fukunami M; Tolvaptan Investigators (2011) Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25 (Suppl 1):S33-S45
21. Mitcheson H, Williams G, and Castro JE (1977) Clinical aspects of polycystic disease of the kidneys. BMJ 1:1196-1199
22. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, and Pierides A, et al. (1996) PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272(5266, S266)1339-1342
23. Mori K and Nakao K (2007) Neutrophil gelatinase-Associated lipocalin as the realtime indicator of active kidney damage. Kidney Int 71:967-970
24. Mrug M, Zhou J, Woo Y, Cui X, Szalai AJ, Novak J, Churchill GA, and Guay-Woodford LM (2008) Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int 73:63-76
25. Nagao S, Hibino T, Koyama Y, Marunouchi T, Konishi H, and Takahashi H (1991) Strain difference in expression of the adult-type polycystic kidney disease gene, pcy, in the mouse. Jikken Dobutsu 40:45-53
26. Nagao S, Kugita M, Yoshihara D, and Yamaguchi T (2012) Animal models for human polycystic kidney disease. Exp Anim 61:477-488
27. Olbrich H, Fliegauf M, Hoefele J, Kispert A, Otto E, Volz A, Wolf MT, Sasmaz G, Trauer U, and Reinhardt R, et al. (2003) Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat Genet 34:455-459
28. Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, Comer DM, Zeltner R, Tian X, Grantham JJ, and Somlo S (2012) Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int 81:784-790
29. Park HC, Hwang JH, Kang AY, Ro H, Kim MG, An JN, In Park J, Kim SH, Yang J, and Oh YK, et al. (2012) Urinary N-Acetyl-b-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study. BMC Nephrol 13:93-102
30. Reichardt W, Romaker D, Becker A, Buechert M, Walz G, and von Elverfeldt D (2009) Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD. MAGMA 22:143-149
31. Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, and Wallace DP (2011) Tolvaptan inhibits ERK-dependent cell proliferation, Cl? secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 301:F1005-F1013
32. Riera M, Burtey S, and Fontés M (2006) Transcriptome analysis of a rat PKD model: importance of genes involved in extracellular matrix metabolism. Kidney Int 69: 1558-1563
33. Rizk D, Jurkovitz C, Veledar E, Bagby S, Baumgarten DA, Rahbari-Oskoui F, Steinman T, and Chapman AB (2009) Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol 4:560-566
34. Sakaida I, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K, Okada M, and Okita K; ASCITES-DOUBLEBLIND Study Group (2014) Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 44:73-82
35. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355:2099-2112
36. Shoaf SE, Wang Z, Bricmont P, and Mallikaarjun S (2007) Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 47:1498-1507
37. Smith LA, Bukanov NO, Husson H, Russo RJ, Barry TC, Taylor AL, Beier DR, and Ibraghimov-Beskrovnaya O (2006) Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 17:2821-2831
38. Takahashi H, Calvet JP, Dittemore-Hoover DBA, Yoshida K, Grantham JJ, and Gattone VH, 2nd (1991) A hereditary model of slowly progressive polycystic kidney disease in the mouse. J Am Soc Nephrol 1:980-989
39. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, and Czerwiec FS; TEMPO 3:4 Trial Investigators (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407-2418
40. Torres VE and Harris PC (2007) Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 261: 17-31
41. Torres VE, Harris PC, and Pirson Y (2007) Autosomal dominant polycystic kidney disease. Lancet 369:1287-1301
42. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, and Gattone VH, 2nd (2004) Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10:363-364
43. Wallace DP (2011) Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta 1812: 1291-1300
44. Wang X, Gattone VH, 2nd, Harris PC, and Torres VE (2005) Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16:846-851
45. Wang X, Wu Y, Ward CJ, Harris PC, and Torres VE (2008) Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102-108
46. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, and Grantham JJ (1997) Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30:703-709
47. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, and Grantham JJ (2003) Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63:1983-1994
48. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, and Calvet JP (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279:40419-40430
49. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, and Kotosai K, et al. (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287: 860-867
50. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, and Mori T, et al. (1992) Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105:787-791.